Alamar Biosciences, Inc. (ALMR)

Alamar Biosciences, Inc. is a life sciences tools company working in proteomics, the large-scale measurement of proteins. Its goal is to enable blood-based detection of disease at very early stages by measuring low-abundance protein biomarkers.

The company's core technology, NULISA, combines immunoassay chemistry with next-generation sequencing readout to detect hundreds of proteins at once with high sensitivity. Alamar sells the ARGO HT System, an automated instrument for running these assays, together with consumable NULISAseq panels for areas such as inflammation and neurology, and also provides testing services. Its customers include academic researchers, pharmaceutical companies and clinical research organizations.

Alamar is headquartered in Fremont, California, and completed its initial public offering on Nasdaq in 2026.